Hubungan High Sensitivity C-Reactive Protein (Hs CRP) dengan Fibrin Clot Strength (Kekuatan Bekuan Fibrin) Pasca Intervensi Koroner Perkutan di Rumah Sakit Umum Haji Adam Malik
47
DAFTAR PUSTAKA
Abbate, A., Biondi-Zoccal, G.G.L., Agostoni, P., Lipinski, M., Vetrovec, G. 2007.
Recurrent angina after coronary revascularization: a clinical challenge.
European Heart Journal. 28: 1057-1065.
Abrams, J. 2005. Chronic Stable Angina. N Engl J Med. 352: 2524-33.
Anderson, J.L., Adams, C.D., Antman, E.M., Bridges, C.R., Califf, R.M., Casey,
D.E., et al. 2011. Guidelines for the management of patients with unstable
angina/non-ST-elevation myocardial infarction: A report of the American
College of Cardiology Foundation/American Heart Association task force
on practice guidelines. Circulation. 123: e426-e579.
Barua, R.S., Sy, F., Srikanth, S., Huang, G., Javed, U., Buhari, C., et al. 2010.
Acute cigarette smoke exposure reduces clot lysis – association between
altered fibrin architecture and the response to t-PA. Thrombosis Research.
126: 426-30.
Barua, R.S., Sy, F., Srikanth, S., Huang, G., Javed, U., Buhari, C., et al.2010.
Effects of cigarette smoke exposure on clot dynamics and fibrin structure:
An ex vivo investigation. Arterioscler Thromb Vasc Biol. 30: 75-9.
Bassuk, S.S., Ridker, P.M. 2006. C-reactive protein as a tool for risk assessment
in primary prevention. In: Morrow, D.A. editor. Cardiovascular Biomarkers:
Pathophysiology and
Disease Management. New Jersey. Humana
Press.p.237-260.
Buffon, A., Liuzzo, G., Biasucci, L.M., Pasqualetti, P., Ramazzotti, V., Rebuzzi,
A.G., et al. 1999. Preprocedural serum level of c-reactive protein predict
early complications and late restenosis after coronary angioplasty. J Am
Coll Cardiol. 34: 1512-1521.
48
Cannon, C.P., Brindis, R.G., Chaitman, B.R., Cohen, D.J., Cross, J.T., Drozda,
J.P., et al. 2013. ACCF/AHA Key data elements and definition for
measuring the clinical management and outcomes of patients with acute
coronary syncromes and coronary artery disease: a report of the American
College of Cardiology Foundation/American Heart Association task force
on clinical data standards. Circulation. 127: 1052-1089.
Choi, H., Cho, D.H., Shin, H.H., Park, J.B. 2004. Association of high sensitivity
C-reactive protein with coronary heart disease prediction, but not with
carotid atherosclerosis, in patients with hypertension. Circulation. 68: 297303.
DeWinter, R.J., Heyde, G.S., Koch, K.T., Fischer, J., VanStraalen, J.P., Bax, M.,
et al. 2002. The prognostic value of pre-procedural plasma c-reactive
protein in patients undergoing elective coronary angioplasty. Eur Heart J.
23: 960-6.
Dibra, A., Mehilli, J., Braun, S., Hadamitzky, M., Baum, H., Dirschinger, J., et al.
2003. Association between c-reactive protein levels and subsequent cardiac
events among patients with stable angina treated with coronary artery
stenting. Am J Med. 114: 715-22.
Dwyer, G.B. 2014. Physical activity preparticipation screening guidelines. In:
Lupash, E. editor. ACMS’s Resources for the Health Fitness Specialist. 1st
ed.
Philadelphia.Wolters
Kluwer
Health:
Lippincott
Williams&Wilkins.p.25.
Gach, O., Legrand, V., Biessaux, Y., Chapelle, J.P., Vanbelle, S., Pierard, L.A.
2007. Long-term prognostic significance of high-sensitivity C-reactive
protein before and after coronary angioplasty in patients with stable angina
pectoris. Am J Cardiol. 99: 31-5.
49
Ganter, M.T., Hofer, C.K. 2008. Coagulation monitoring, current techniques and
clinical use of viscoelastic point-of-care coagulation device. Anesth Analg.
106: 1366-1375.
Garg, R., Tellez, A., Alviar, C., Granada, J., Kleiman, N.S., Lev, E.I. 2008. The
effect of percutaneous coronary intervention on inflammatory response and
endotelial progenitor cell recruitment. Catheterization and cardiovascular
interventions. 72: 205-9.
Gregory, Y.H., Blann, A.D. 2000. Does hypertension confer a prothrombotic
state? Virchow’s triad revisited. Circulation. 101: 218-20.
Gurbel, P.A., Bliden, K.P., Guyer, K., Cho, P.W., Zaman, K.A., Kreutz, R.P., et
al. 2005. Platelet reactivity in patients and recurrent events post-stenting. J
Am Coll Cardiol. 46: 1820-1826.
Hansson, G.K. 2005. Inflammation, atherosclerosis, and coronary artery disease.
N. Engl. J. Med. 352: 1685-1695.
Haverkate, F., Thompson, S.G., Pyke, S.D., Gallimore, J.R., Pepys, M.B. 1997.
Production of c-reactive protein and risk of coronary events in stable and
unstable angina: European concerted action on thrombosis and disabilities
angina pectoris study group. Lancet. 349: 462-466.
Holmes, D.R., Kereiakes D.J., Garg, S., Serruys P.W., Dehmer, G.J., Ellis, S.G.,
et al. 2010. Stent thrombosis. J Am Coll Cardiol. 56: 1357-65.
Hoshida, S., Nishino, M., Takeda, T., Tanouchi, J., Yamada, Y., Hori, M. 2004. A
persistent increase in c-reactive protein in a risk factor for restenosis in
patients with stable angina who are not receiving statins. Atherosclerosis.
173: 285-90.
50
Inoue, T., Kato, T., Uchida, T., Sakuma, M., Nakajima, A., Shibazaki, M., et al.
2005. Local release of c-reactive protein from vulnerable plaque or coronary
arterial wall injured by stenting. J Am Coll Cardiol. 46: 239-245.
Kaptoge, S., Di Angelantonia, E., Lowe, G., Pepys, M.B., Thompson, S.G.,
Collins, R., et al. 2010. C-reactive protein concentration and risk of
coronary heart disease, stroke, and mortality: an individual meta-analysis.
Lancet. 375: 132-140.
Khera, A., McGuire, D.K., Murphy, S.A., Stanek, H.G., Das, S.R.,
Vongpatanasin, W., et al. 2005. Race and gender differences in c-reactive
protein levels. J Am Coll Cardiol. 46: 464-9.
Kralisz, P., Kemona, H., Dobrzycki, S., Bachorzewska-Gajewska, H., Nowak, K.,
Sawicki, Z. 2006. Changes in c-reactive protein levels following coronary
stent implantation depend on the extent of peroprocedural arterial injury.
Kardiol Pol. 64: 364-371.
Kreutz, R.P., Owens, J., Breall, J.A., Lu, D., Lohe E., Bolad, I., et al. 2013. Creactive protein and fibrin clot strength measured by thromboelastography
after coronary stenting. Blood Coagul Fibrinolysis. 24: 321-326.
Libby, P. 2006. Inflammation in cardiovascular disease. In: Morrow, D.A. editor.
Cardiovascular Biomarkers: Pathophysiology and Disease Management.
New Jersey. Humana Press.p.207-221.
Libby, P., Ridker, P.M., Hansson, G.K. 2009. Inflammation in atherosclerosis. J
Am Coll Cardiol. 54: 2129-38.
Liuzzo, G., Biasucci, L.M., Gallimore, J.R., Grillo, R.L., Rebizzu, A.G., Pepys,
M.B., et al. 1994. The prognostic value of c-reactive protein and serum
51
amyloid a protein in severe unstable angina pectoris. N. Engl J Med. 331:
417-424.
Mansfield, M.W., Heywood, P.M., Grant, P.J. 1996. Sex differences in
coagulation and fibrinolysis in white subjects with non-insulin dependent
diabetes mellitus. Atherosclerosis, Thrombosis, and Vascular Biology. 16:
160-4.
McCrath, D., Cerboni, E., Hirsh, A., Frumento R.J., Bennet-Guerrero, E. 2003.
Association of thromboelastography (MA) and thrombotic complications
after major non-cardiac surgery. Anesth Analog. 96:SCA1-141.
Nakagomi, A., Freedmann, S.B., Geczy, C.L. 2000. Interferon-gamma and
lipopolysaccharide potentiate monocyte tissue factor induction by c-reactive
protein relationship with age, sex, and hormone replacement treatment.
Circulation. 101: 1785-91.
Nyandak, T., Gogna, A., Bansal, S., Deb, M. 2007. High sensitive c-reactive
protein (hs-CRP) and its correlation with angiographic severity of coronary
artery disease. JIACM. 8: 217-221.
Park, D., Yun, S., Lee, J., Kim, W., Kang, S., Lee, S., et al. 2009. C-reactive
protein and the risk of stent thrombosis and cardiovascular events after
drug-eluting stent implantation. Circulation. 120: 1987-1995.
Ridker, P.M., Cannon, C.P., Morrow, D., et al. 2005. C-reactive protein levels and
outcomes after statin therapy. N Eng J Med. 352: 20-8.
Rifai, N. 2006. Analytic issues for clinical use of c-reactive protein. In: Morrow,
D.A. editor. Cardiovascular Biomarkers: Pathophysiology and Disease
Management. New Jersey. Humana Press.p.223-235.
52
Rifai, N., Ridker, P.M. 2001. High-sensitivity c-reactive protein: A novel and
promising marker of coronary heart disease. Clinical Chemistry. 47: 403411.
Song, C.J., Nakagomi, A., Chandar, S., Cai, H., Lim, I.G.S., McNeil, H.P., et al.
2006. C-reactive protein contributes to the hypercoagulable state in coronary
artery disease. J Thromb Haemost. 4: 98-106.
Steinhubl, S., Berger, P., Mann, J.T., Fry, E.T.A., DeLago, A., Wilmer, C. et.al.
2007. Early and sustained dual oral antiplatelet therapy following
percutaneous coronary intervention. JAMA. 288: 2411-2420.
Thakur, M., Ahmed, A.B. 2012. A review of thromboelastography. International
Journal of Perioperative Ultrasound and Applied Technologies. 1: 25-29.
Thygesen, K., Alpert J.S., Jaffe, A.S., Simoons, M.L., Chaitman, B.R., White,
H.D. 2012. Third universal definition of myocardial infarction. European
Heart Journal. doi:10.1093/eurheartj/ehs184
Toutouzas, K., Colombo, A., Stefanadis, C. 2004. Inflammation and restenosis
after percutaneous coronary interventions. European Heart Journal. 25:
1679-1687.
Undas, A., Areins, R.A.S. 2011. Fibrin clot structure and fuction: A role in the
pathophysiology thromboembolic disease. Arterioscler Thromb Vasc Biol.
31: e88-e99.
Undas, A., Plicner, D., Stepien, E., Drwila, R., Sadowski, J. 2007. Altered fibrin
clot structure in patients with advances coronary artery disease: a role of Creactive protein, lipoprotein(a), and homocysteine. J Thromb Haemost. 5:
1988-90.
53
Undas, A., Zalewski, J., Krochin, M., Siudak, Z., Sadowski, M., Pregowski, J., et
al. 2010. Altered plasma fibrin clot properties are associated with in-stent
thrombosis. Arteriscler Thromb Vasc Biol. 30: 276-282.
Weintraub, W.S., Karlsberg, R.P., Tcheng, J.E., Boris, J.R., Buxton, A.E., Dove,
J.T., et al. 2011. Key data elements and definition of a bas cardiovascular
vocabulary for electronic health records. J Am Coll Cardiol. 58: 202-222.
Zalewski, J., Undas, A., Godlewski, J., Stepien, E., Zmudka, K. 2007. No-reflow
phenomenon after acute myocardial infarction is associated with reduced
clot permeability and susceptibility to lysis. Arteriscler Thromb Vasc Biol.
27: 2258-2265.
DAFTAR PUSTAKA
Abbate, A., Biondi-Zoccal, G.G.L., Agostoni, P., Lipinski, M., Vetrovec, G. 2007.
Recurrent angina after coronary revascularization: a clinical challenge.
European Heart Journal. 28: 1057-1065.
Abrams, J. 2005. Chronic Stable Angina. N Engl J Med. 352: 2524-33.
Anderson, J.L., Adams, C.D., Antman, E.M., Bridges, C.R., Califf, R.M., Casey,
D.E., et al. 2011. Guidelines for the management of patients with unstable
angina/non-ST-elevation myocardial infarction: A report of the American
College of Cardiology Foundation/American Heart Association task force
on practice guidelines. Circulation. 123: e426-e579.
Barua, R.S., Sy, F., Srikanth, S., Huang, G., Javed, U., Buhari, C., et al. 2010.
Acute cigarette smoke exposure reduces clot lysis – association between
altered fibrin architecture and the response to t-PA. Thrombosis Research.
126: 426-30.
Barua, R.S., Sy, F., Srikanth, S., Huang, G., Javed, U., Buhari, C., et al.2010.
Effects of cigarette smoke exposure on clot dynamics and fibrin structure:
An ex vivo investigation. Arterioscler Thromb Vasc Biol. 30: 75-9.
Bassuk, S.S., Ridker, P.M. 2006. C-reactive protein as a tool for risk assessment
in primary prevention. In: Morrow, D.A. editor. Cardiovascular Biomarkers:
Pathophysiology and
Disease Management. New Jersey. Humana
Press.p.237-260.
Buffon, A., Liuzzo, G., Biasucci, L.M., Pasqualetti, P., Ramazzotti, V., Rebuzzi,
A.G., et al. 1999. Preprocedural serum level of c-reactive protein predict
early complications and late restenosis after coronary angioplasty. J Am
Coll Cardiol. 34: 1512-1521.
48
Cannon, C.P., Brindis, R.G., Chaitman, B.R., Cohen, D.J., Cross, J.T., Drozda,
J.P., et al. 2013. ACCF/AHA Key data elements and definition for
measuring the clinical management and outcomes of patients with acute
coronary syncromes and coronary artery disease: a report of the American
College of Cardiology Foundation/American Heart Association task force
on clinical data standards. Circulation. 127: 1052-1089.
Choi, H., Cho, D.H., Shin, H.H., Park, J.B. 2004. Association of high sensitivity
C-reactive protein with coronary heart disease prediction, but not with
carotid atherosclerosis, in patients with hypertension. Circulation. 68: 297303.
DeWinter, R.J., Heyde, G.S., Koch, K.T., Fischer, J., VanStraalen, J.P., Bax, M.,
et al. 2002. The prognostic value of pre-procedural plasma c-reactive
protein in patients undergoing elective coronary angioplasty. Eur Heart J.
23: 960-6.
Dibra, A., Mehilli, J., Braun, S., Hadamitzky, M., Baum, H., Dirschinger, J., et al.
2003. Association between c-reactive protein levels and subsequent cardiac
events among patients with stable angina treated with coronary artery
stenting. Am J Med. 114: 715-22.
Dwyer, G.B. 2014. Physical activity preparticipation screening guidelines. In:
Lupash, E. editor. ACMS’s Resources for the Health Fitness Specialist. 1st
ed.
Philadelphia.Wolters
Kluwer
Health:
Lippincott
Williams&Wilkins.p.25.
Gach, O., Legrand, V., Biessaux, Y., Chapelle, J.P., Vanbelle, S., Pierard, L.A.
2007. Long-term prognostic significance of high-sensitivity C-reactive
protein before and after coronary angioplasty in patients with stable angina
pectoris. Am J Cardiol. 99: 31-5.
49
Ganter, M.T., Hofer, C.K. 2008. Coagulation monitoring, current techniques and
clinical use of viscoelastic point-of-care coagulation device. Anesth Analg.
106: 1366-1375.
Garg, R., Tellez, A., Alviar, C., Granada, J., Kleiman, N.S., Lev, E.I. 2008. The
effect of percutaneous coronary intervention on inflammatory response and
endotelial progenitor cell recruitment. Catheterization and cardiovascular
interventions. 72: 205-9.
Gregory, Y.H., Blann, A.D. 2000. Does hypertension confer a prothrombotic
state? Virchow’s triad revisited. Circulation. 101: 218-20.
Gurbel, P.A., Bliden, K.P., Guyer, K., Cho, P.W., Zaman, K.A., Kreutz, R.P., et
al. 2005. Platelet reactivity in patients and recurrent events post-stenting. J
Am Coll Cardiol. 46: 1820-1826.
Hansson, G.K. 2005. Inflammation, atherosclerosis, and coronary artery disease.
N. Engl. J. Med. 352: 1685-1695.
Haverkate, F., Thompson, S.G., Pyke, S.D., Gallimore, J.R., Pepys, M.B. 1997.
Production of c-reactive protein and risk of coronary events in stable and
unstable angina: European concerted action on thrombosis and disabilities
angina pectoris study group. Lancet. 349: 462-466.
Holmes, D.R., Kereiakes D.J., Garg, S., Serruys P.W., Dehmer, G.J., Ellis, S.G.,
et al. 2010. Stent thrombosis. J Am Coll Cardiol. 56: 1357-65.
Hoshida, S., Nishino, M., Takeda, T., Tanouchi, J., Yamada, Y., Hori, M. 2004. A
persistent increase in c-reactive protein in a risk factor for restenosis in
patients with stable angina who are not receiving statins. Atherosclerosis.
173: 285-90.
50
Inoue, T., Kato, T., Uchida, T., Sakuma, M., Nakajima, A., Shibazaki, M., et al.
2005. Local release of c-reactive protein from vulnerable plaque or coronary
arterial wall injured by stenting. J Am Coll Cardiol. 46: 239-245.
Kaptoge, S., Di Angelantonia, E., Lowe, G., Pepys, M.B., Thompson, S.G.,
Collins, R., et al. 2010. C-reactive protein concentration and risk of
coronary heart disease, stroke, and mortality: an individual meta-analysis.
Lancet. 375: 132-140.
Khera, A., McGuire, D.K., Murphy, S.A., Stanek, H.G., Das, S.R.,
Vongpatanasin, W., et al. 2005. Race and gender differences in c-reactive
protein levels. J Am Coll Cardiol. 46: 464-9.
Kralisz, P., Kemona, H., Dobrzycki, S., Bachorzewska-Gajewska, H., Nowak, K.,
Sawicki, Z. 2006. Changes in c-reactive protein levels following coronary
stent implantation depend on the extent of peroprocedural arterial injury.
Kardiol Pol. 64: 364-371.
Kreutz, R.P., Owens, J., Breall, J.A., Lu, D., Lohe E., Bolad, I., et al. 2013. Creactive protein and fibrin clot strength measured by thromboelastography
after coronary stenting. Blood Coagul Fibrinolysis. 24: 321-326.
Libby, P. 2006. Inflammation in cardiovascular disease. In: Morrow, D.A. editor.
Cardiovascular Biomarkers: Pathophysiology and Disease Management.
New Jersey. Humana Press.p.207-221.
Libby, P., Ridker, P.M., Hansson, G.K. 2009. Inflammation in atherosclerosis. J
Am Coll Cardiol. 54: 2129-38.
Liuzzo, G., Biasucci, L.M., Gallimore, J.R., Grillo, R.L., Rebizzu, A.G., Pepys,
M.B., et al. 1994. The prognostic value of c-reactive protein and serum
51
amyloid a protein in severe unstable angina pectoris. N. Engl J Med. 331:
417-424.
Mansfield, M.W., Heywood, P.M., Grant, P.J. 1996. Sex differences in
coagulation and fibrinolysis in white subjects with non-insulin dependent
diabetes mellitus. Atherosclerosis, Thrombosis, and Vascular Biology. 16:
160-4.
McCrath, D., Cerboni, E., Hirsh, A., Frumento R.J., Bennet-Guerrero, E. 2003.
Association of thromboelastography (MA) and thrombotic complications
after major non-cardiac surgery. Anesth Analog. 96:SCA1-141.
Nakagomi, A., Freedmann, S.B., Geczy, C.L. 2000. Interferon-gamma and
lipopolysaccharide potentiate monocyte tissue factor induction by c-reactive
protein relationship with age, sex, and hormone replacement treatment.
Circulation. 101: 1785-91.
Nyandak, T., Gogna, A., Bansal, S., Deb, M. 2007. High sensitive c-reactive
protein (hs-CRP) and its correlation with angiographic severity of coronary
artery disease. JIACM. 8: 217-221.
Park, D., Yun, S., Lee, J., Kim, W., Kang, S., Lee, S., et al. 2009. C-reactive
protein and the risk of stent thrombosis and cardiovascular events after
drug-eluting stent implantation. Circulation. 120: 1987-1995.
Ridker, P.M., Cannon, C.P., Morrow, D., et al. 2005. C-reactive protein levels and
outcomes after statin therapy. N Eng J Med. 352: 20-8.
Rifai, N. 2006. Analytic issues for clinical use of c-reactive protein. In: Morrow,
D.A. editor. Cardiovascular Biomarkers: Pathophysiology and Disease
Management. New Jersey. Humana Press.p.223-235.
52
Rifai, N., Ridker, P.M. 2001. High-sensitivity c-reactive protein: A novel and
promising marker of coronary heart disease. Clinical Chemistry. 47: 403411.
Song, C.J., Nakagomi, A., Chandar, S., Cai, H., Lim, I.G.S., McNeil, H.P., et al.
2006. C-reactive protein contributes to the hypercoagulable state in coronary
artery disease. J Thromb Haemost. 4: 98-106.
Steinhubl, S., Berger, P., Mann, J.T., Fry, E.T.A., DeLago, A., Wilmer, C. et.al.
2007. Early and sustained dual oral antiplatelet therapy following
percutaneous coronary intervention. JAMA. 288: 2411-2420.
Thakur, M., Ahmed, A.B. 2012. A review of thromboelastography. International
Journal of Perioperative Ultrasound and Applied Technologies. 1: 25-29.
Thygesen, K., Alpert J.S., Jaffe, A.S., Simoons, M.L., Chaitman, B.R., White,
H.D. 2012. Third universal definition of myocardial infarction. European
Heart Journal. doi:10.1093/eurheartj/ehs184
Toutouzas, K., Colombo, A., Stefanadis, C. 2004. Inflammation and restenosis
after percutaneous coronary interventions. European Heart Journal. 25:
1679-1687.
Undas, A., Areins, R.A.S. 2011. Fibrin clot structure and fuction: A role in the
pathophysiology thromboembolic disease. Arterioscler Thromb Vasc Biol.
31: e88-e99.
Undas, A., Plicner, D., Stepien, E., Drwila, R., Sadowski, J. 2007. Altered fibrin
clot structure in patients with advances coronary artery disease: a role of Creactive protein, lipoprotein(a), and homocysteine. J Thromb Haemost. 5:
1988-90.
53
Undas, A., Zalewski, J., Krochin, M., Siudak, Z., Sadowski, M., Pregowski, J., et
al. 2010. Altered plasma fibrin clot properties are associated with in-stent
thrombosis. Arteriscler Thromb Vasc Biol. 30: 276-282.
Weintraub, W.S., Karlsberg, R.P., Tcheng, J.E., Boris, J.R., Buxton, A.E., Dove,
J.T., et al. 2011. Key data elements and definition of a bas cardiovascular
vocabulary for electronic health records. J Am Coll Cardiol. 58: 202-222.
Zalewski, J., Undas, A., Godlewski, J., Stepien, E., Zmudka, K. 2007. No-reflow
phenomenon after acute myocardial infarction is associated with reduced
clot permeability and susceptibility to lysis. Arteriscler Thromb Vasc Biol.
27: 2258-2265.